AMAXA provides a wide range of medicines designed to improve health and save lives.
A significant portion of AMAXA products is anticancer drugs. These medicines are used to treat breast cancer, ovarian cancer, Kaposi’s sarcoma, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, malignant lymphoma and other cancers. Our oncology portfolio includes drugs based on gemcitabine, oxaliplatin, paclitaxel and vinorelbine, as well as other molecules used in oncology.
Successful treatment of cancer largely depends on selecting the appropriate treatment. AMAXA plays a major role in this important stage by carrying out molecular testing of tumour sensitivity to different drugs.
We help develop the most effective treatment plan for each patient individually by carefully analysing biomarkers against a broad base of information.
Neurological group preparations are designed to treat patients with brain injuries and cerebral pathologies.
Our line of immunobiological preparations is represented by immunoglobulins for intravenous administration, solutions of albumin and prothrombin complex for prevention and control of bleeding.
We also offer a number of OTC drugs aimed at the treatment of throat inflammatory diseases, urinary tract infections, chronic venous insufficiency, menopausal disorders in women and prevention of abnormal scarring after surgery.
AMAXA product portfolio reflects our mission to provide people with quality medical supplies and services. We have very high requirements for each drug, the main criteria being:
Note: The list of products available for different countries may vary. For more information on our full list of products, please email a request to firstname.lastname@example.org